Publication Name	World Journal of Diabetes
Manuscript ID	58060
Country	Greece

Received	2020-07-05 06:24
Peer-Review Started	2020-07-05 06:24
To Make the First Decision
Return for Revision	2020-07-30 18:01
Revised	2020-08-02 19:51
Second Decision	2020-09-03 10:25
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2020-09-03 16:16
Articles in Press	2020-09-03 16:16
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2020-09-07 00:28
Publish the Manuscript Online	2020-09-11 07:11

ISSN	1948-9358 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Endocrinology & Metabolism
Manuscript Type	Editorial
Article Title	Is there a role for glucagon-like peptide-1 receptor agonists in the management of diabetic nephropathy?
Manuscript Source	Invited Manuscript
All Author List	Stavroula Veneti and Konstantinos Tziomalos
Funding Agency and Grant Number
Corresponding Author	Konstantinos Tziomalos, MD, MSc, PhD, Associate Professor, First Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, 1 Stilponos Kyriakidi Street, Thessaloniki 54636, Greece. ktziomalos@yahoo.com
Key Words	Diabetic nephropathy; Type 2 diabetes mellitus; Glucagon-like peptide-1 receptor agonists; Liraglutide; Dulaglutide; Semaglutide
Core Tip	Glucagon-like peptide-1 receptor agonists prevent the development of persistent macroalbuminuria in patients with type 2 diabetes mellitus. However, it is unclear whether they delay the decline in glomerular filtration rate in this population. Long-term trials are needed to clarify the role of these agents in the management of diabetic nephropathy.
Publish Date	2020-09-11 07:11
Citation	Veneti S, Tziomalos K. Is there a role for glucagon-like peptide-1 receptor agonists in the management of diabetic nephropathy? World J Diabetes 2020; 11(9): 370-373
URL	https://www.wjgnet.com/1948-9358/full/v11/i9/370.htm
DOI	https://dx.doi.org/10.4239/wjd.v11.i9.370

Full Article (PDF)	WJD-11-370.pdf
Full Article (Word)	WJD-11-370.docx
Manuscript File	58060-Review.docx
Answering Reviewers	58060-Answering reviewers.pdf
Audio Core Tip	58060-Audio core tip.wma
Conflict-of-Interest Disclosure Form	58060-Conflict-of-interest statement.pdf
Copyright License Agreement	58060-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	58060-Language certificate.pdf
Peer-review Report	58060-Peer-review(s).pdf
Scientific Misconduct Check	58060-Scientific misconduct check.pdf
Scientific Editor Work List	58060-Scientific editor work list.pdf